1xbet 신청., Ltd.
1xbet 신청s
April 20, 2016
1xbet 신청's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to 1xbet 신청 development of novel small molecule oncology 1xbet 신청rapeutics, announced on April 19 that it has entered into a clinical collaboration with Genentech.
1xbet 신청 collaboration will evaluate 1xbet 신청 potential for combining Astex's next-generation hypomethylating agent, guadecitabine (SGI-110), with Genentech's investigational anti-PD-L1 monoclonal antibody, atezolizumab, in 1xbet 신청 treatment of acute myeloid leukemia (AML). An initial Phase 1b study will investigate 1xbet 신청 safety and pharmacology of 1xbet 신청 combination.
For more information about Astex 1xbet 신청s, please visithttp://www.astx.1xbet 신청
Latest 1xbet 신청 Business related News Releases